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Arthur L. BeaudetEditorial summary
Expanded genetic carrier testing is changing clinical
practice. Current experience highlights the need for
rigorous curation of tens of thousands of variants as
to their pathogenicity and phenotypic effects. There is
an urgent need for strategies to present a range of
options to families to enable them to make informed
decisions. The potential exists to avoid the great
majority of serious inherited, but not de novo, single-
gene disabilities.complete understanding possible of variant-to-phenotypeRapid proliferation
For decades, genetic carrier testing has referred primar-
ily to testing with the aim of identifying heterozygote
carriers of mutations that put a mating of two carriers at
a one in four risk of having a child with a disorder caus-
ing serious disability or early death. This type of testing
began in the early 1970s with Tay-Sachs disease in the
Ashkenazi Jewish population [1]. Screening programs
focused on β-thalassemia were implemented in the
Mediterranean region around 1980, as well as some pro-
grams for sickle cell anemia. The identification of the
cystic fibrosis gene in 1989 [2] led to immediate imple-
mentation of carrier testing for this disease.
By 1993 [3], the term 'universal carrier testing' was
used in the context of cystic fibrosis to imply testing
the entire population regardless of ethnicity or family
history. In 2010, the biotechnology company Counsyl,
Inc. proposed 'universal carrier testing' to mean testing
more than 100 genes and talked of “the long tail of
Mendelian disease”, implying the possibility of testing
for all Mendelian diseases even if relatively rare [4].
Although Counsyl used genotyping technology, Bell
et al. in 2011 [5] were the first group to use next-
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of expanded carrier testing programs, and it would be
only a small step further to use whole-exome or whole-
genome sequencing for carrier detection.
Providers are switching to full sequencing of all coding
exons and associated regions known to harbor patho-
genic mutations. This increased activity forces us to
consider how to analyze the data, and we propose the
creation of a triple-global database: global first to include
all human populations, global second to include the
entire genome, and global third to include the most
relationships. The Human Variome Project [6] and the
ClinVar database [7] are efforts in this direction. The
phenotypic variation associated with each variant must be
determined as distinct from pathogenicity. For example,
there might be equally high confidence of pathogenicity
for two variants in HEXA, but one may cause infantile
Tay-Sachs while another causes an adult chronic pheno-
type. The phenotypic effect will often be the result of
two variants in a compound heterozygous state. One
source for this global database could be to determine
the disease-causing mutations in the majority of indi-
viduals across the globe with severe autosomal recessive
or X-linked disorders.Current practice
Although the term 'carrier' is most often used to desig-
nate individuals with heterozygous recessive mutations
in autosomal genes, the term can also be used to de-
scribe carriers of mutations in X-linked genes, carriers
of copy-number variants (CNVs), carriers of dominant
mutations such as those in BRCA1 and BRCA2 (which
are associated with the risks of breast and ovarian
cancer), carriers of common single nucleotide polymor-
phisms (SNPs), and carriers of balanced chromosomal
translocations.
At present, carrier testing most commonly involves a
gene panel with dozens to hundreds of genes. The disor-
ders most widely screened for are cystic fibrosis, diseasese distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Beaudet Genome Medicine  (2015) 7:79 Page 2 of 3associated with Ashkenazi ethnicity, hemoglobinopa-
thies, spinal muscular atrophy, and fragile X syndrome.
In addition to NGS, various forms of copy number ana-
lysis are used to detect large deletions and duplications,
such as those relevant for Duchenne muscular dystrophy
and NPHP1-caused nephronophthesis, as well as MECP2
and SMN1 duplications and other CNVs.
A recent statement on expanded carrier screening
from multiple professional organizations provides an
overview of current practices [8]. This statement covers
many important topics, which cannot be covered in the
space available here, including residual risk, relationship
with newborn screening, the difficulties presented by
pseudogenes, screening gamete donors, the importance
of knowing paternity, and the detection of milder or
incompletely penetrant variants and disorders.
Many genes currently being tested relate to severe
phenotypes for which therapy is inadequate. Diseases
such as Tay-Sachs, Krabbe, and fragile X syndrome are
examples for which strong justification exists. Cystic
fibrosis and congenital deafness are also often consid-
ered in this severe disease group, although they do not
involve intellectual disability and some good treatments
are available. Screening for these disorders is usually
predicated on the expectation that at least some families
will want to avoid the birth of affected children, either
through termination of affected pregnancies or perhaps
through the use of preimplantation genetic diagnosis
(PGD) or donor gametes if risk is identified prior to
conception. However, many other disorders for which
carrier testing seems less compelling but perhaps not
harmful are being tested, including phenylketonuria and
medium-chain acyl-CoA dehydrogenase (MCAD) defi-
ciency; these are disorders for which newborn screening
and excellent treatments are available. Other disorders,
such as hereditary fructose intolerance, Wilson disease,
and glucose-galactose malabsorption, are usually not
detected by newborn screening, and early and accurate
diagnosis can be extremely beneficial and even life-
saving.
One vision for the future
The trend towards expanded screening is likely to grow,
with a longer and longer list of genes being analyzed in
an attempt to address the “long tail of Mendelian dis-
ease”. The need for correct interpretation of the data
provided by these sequencing approaches emphasizes
the usefulness of a triple-global database of human
gene variation, as noted above. The development and
refinement of this database will be a mammoth task,
but it need only be done once per human civilization,
and the effort required for its maintenance and updat-
ing will be trivial by comparison with that required for
its initial construction.If we were to use whole-genome or whole-exome se-
quencing as a carrier test, the burden of severe Mendelian
disabilities in the population could be dramatically re-
duced. The incidence of individual recessive disorders
varies widely across the globe, presumably largely re-
lated to founder effects and some selection for hetero-
zygote advantage. Apart from the data on globin
disorders collected by the World Health Organization
[9], the combined incidence of all recessive disorders
and the incidence of individual disorders are generally
unknown for most of the very large country-level popu-
lations, such as those in China, India, and Indonesia.
The incidence of recessive disorders is higher in popu-
lations in which consanguinity is common. If health
care systems across the globe supported carrier detec-
tion for recessive and dominant variants and funded
the use of PGD to avoid serious disabilities, the tools
that are already available could dramatically reduce the
frequency of inherited, but not de novo, cases of severe
Mendelian disabilities without a single abortion. One
criticism will be that this is prohibitively expensive, but
the burden of severe Mendelian disease is also very
expensive for society. For dominant disorders that
occur mostly through inherited rather than de novo
mutations (e.g., BRCA1/2 and HNPCC mutations that
lead to hereditary nonpolyposis colon cancer), such an
approach would dramatically reduce the frequency of
these disorders in a single generation and for all gener-
ations to come except for new mutations.
For defining pathogenicity of each variant, one option
might be as follows: score all inactivating (loss-of-function)
variants as 'carrier (pathogenic)' if specific exclusions
are made for exceptions (e.g., stop codons in last exons
or alternatively spliced exons); score missense variants
with appropriate frequency and no contrary evidence as
'carrier (pathogenic)' if the variant was found in trans
with pathogenic variants (ITWPV) in at least five af-
fected families; score missense variants as 'carrier, mod-
erate evidence (likely pathogenic)' if the variant was
detected ITWPV in three or four affected families and
as 'carrier, weak evidence' (equivalent to 'variant of un-
known significance-favor pathogenic' [VUS-FP]; a term
suggested by Heidi Rehm, personal communication) if
the variant was detected ITWPV in one or two affected
families; score missense variants that have never been
reported to cause disease as VUS and do not report
these. This strategy ignores computational assessments
of pathogenicity, although this situation could change if
these tools became more predictive. Many variants
reported to be pathogenic in one or two families and
described as 'likely pathogenic' in various databases are
almost certainly benign. A major effort is needed to
reclassify such variants properly. Each variant should
also be given a phenotypic score, which in most cases
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gous or hemizygous loss-of-function variants or with
well-characterized missense variants (e.g., sickle cell),
but many variants are associated with milder pheno-
types which must be explained when known.
Individuals with a variant identified as 'carrier, weak
evidence' or 'carrier, moderate evidence' present a di-
lemma. If these variants are reported, a couple might be
falsely identified as being at risk of having affected off-
spring, whereas if the variants are not reported there is
risk of identifying a couple as not at risk and then having
the birth of an unanticipated affected child. The second
harm seems greater than the first. In most cases, the
partner of the possible carrier will be a noncarrier and
the concern can be dropped. Rarely, the partner will be
a carrier and special efforts such as functional studies
could be undertaken. If the data are worrisome enough,
a couple would always have the option to avoid the am-
biguous genotype via PGD or termination of pregnancy.
There is a desire on the part of some clinicians and pa-
tients to have an option to exclude disorders that are un-
likely to alter reproductive plans and to exclude variants
with very mild phenotypes and/or only weak evidence of
pathogenicity, versus a second option to test and report
variants as comprehensively as possible. An option re-
stricted to variants associated with more severe pheno-
types can be offered. Some variants that are common in
various subpopulations across the globe especially raise
questions about whether they should be reported or
not. These include milder variants in G6PD; homozy-
gous or heterozygous deletion of one of the α-globin
genes but not of the cis copy; the S and Z variants for
α-1-antytrypsin; variants in CFTR causing congenital
bilateral absence of the vas deferens; and the mildly
deleterious 5T allele of the poly-T tract variation in
intron 8 of CFTR. Reporting these variants or not dra-
matically affects the fractions of individuals who will
have a positive test report.
Conclusion
With increasing breadth of testing, concurrent testing of
both partners is far superior to sequential testing, as the
reproductive risks are determined by the combined data.
Also, expansion of the gene list means that an increasing
proportion of tested individuals will be a carrier for one
or other disorder leading to sequential testing of the
partner. Undue anxiety and inefficiency can be avoided
by concurrent testing. Preconception testing is far super-
ior to testing during pregnancy, as options such as PGD
are available. Testing for X-linked disorders and for
dominant mutations should be given increasing atten-
tion going forward. Carrier testing for pathogenic CNVs
of varying severity and penetrance should also be an op-
tion (e.g., deletions and duplications of the DiGeorgeand Williams syndrome regions). Cascade testing, de-
fined as prioritized testing of individuals on the basis of
degree of relatedness to a known carrier [10], is highly
desirable and is made more effective by testing both
partners. Cascade testing is particularly valuable for
dominant mutations such as those in BRCA1/2 or in
HNPCC genes. One option might be to include testing
for so-called actionable genes [11], such as the gene
encoding LDL receptor (LRLR). If one envisions exome
sequencing or genome sequencing of couples prior to
reproduction, one could also include more general forms
of testing such as a pharmacogenetic panel.
In summary, expanded carrier testing is medically jus-
tifiable, but involves challenges in genetic counseling
and great complexity in the interpretation of the patho-
genicity and phenoytypic effect of each variant. Testing
can be restricted to reproductive decisions or expanded
to include actionable gene analysis. A massive and pub-
licly accessible database will be needed to maximize
benefit and minimize harms of expanded carrier testing.
Expanded carrier testing makes it potentially feasible to
avoid the great majority of serious inherited, but not de
novo, single-gene disabilities.References
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